13F Holdings
中文EN

CELU Celularity Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%

Returns

ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$26.55M$54.22M$22.77M$17.98M$21.34M
Cost of revenue$20.07M$14.99M$16.02M——
Gross profit$6.48M$39.23M$6.75M-$1.69M$11.68M
R&D expense$15.03M$17.39M$30.46M$78.36M$88.35M
SG&A expense$51.27M$58.64M$50.58M$66.02M$71.34M
Operating income-$61.31M-$38.36M-$192.29M-$25.60M-$109.06M
Pretax income-$91.71M-$57.89M-$196.28M$14.21M-$100.10M
Income tax$3,000—$10,000$13,000$20,000
Net income-$91.72M-$57.89M-$196.29M$14.19M-$100.12M
EBITDA-$54.01M-$30.44M-$182.96M-$16.16M-$100.24M
EPS (basic)-3.59-2.64-11.021.01-1.49
EPS (diluted)-3.59-2.64-11.020.95-1.49
Weighted avg. shares (diluted)25.60M21.89M17.81M14.98M67.06M
Balance sheet
Cash & equivalents$6.17M$10.98M$10.16M$28.80M$52.08M
Receivables$4.65M————
Inventory$571,000$5.41M$5.75M$5.31M$9.55M
Current assets$12.32M$20.56M$19.79M$33.50M$59.10M
PP&E, net$55.80M$61.60M$67.83M$75.66M$90.62M
Goodwill$7.35M$7.35M$7.35M$119.69M$123.30M
Intangibles$7.76M$9.25M$11.00M$120.99M$123.19M
Total assets$107.33M$132.68M$143.89M$401.07M$414.13M
Current liabilities$80.76M$53.68M$67.30M$62.09M$26.23M
Short-term debt——$39.24M$37.60M—
Long-term debt$33.81M————
Total debt$33.81M————
Total liabilities$145.39M$123.84M$102.93M$202.16M$314.71M
Shareholders' equity-$38.06M$8.84M$40.96M$198.90M$99.42M
Net debt$27.64M————
Shares outstanding28.84M22.55M19.38M14.89M124.31M
Cash flow statement
Operating cash flow-$13.25M-$6.40M-$38.69M-$137.88M-$110.10M
Capital expenditure—$161,000$1.05M$5.24M$6.20M
Free cash flow—-$6.56M-$39.73M-$143.11M-$116.30M
Investing cash flow—$514,000-$4.05M-$5.24M-$5.90M
Financing cash flow$18.65M$6.70M$24.09M$119.84M$98.56M
Depreciation & amortization$7.29M$7.92M$9.32M$9.44M$8.82M
Stock-based compensation$10.64M$11.57M$0$15.86M$40.01M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.